ERBB2 and breast carcinoma: Due to their attractive properties, numerous research groups have developed aptamers targeting HER2 either as single agents or in combination with multiple drugs and nanomaterials for treating HER2-positive breast cancers (Jiang et al., 2017; Zhu et al., 2017; Liu et al., 2018).